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HIGHLIGHTS 
 Mouse models have been instrumental in defining pathogenic mechanisms in 
preeclampsia and in the identification of statins as a potential treatment. 
 Numerous epidemiological studies provided robust evidence demonstrating that 
pravastatin exposure during pregnancy does not affect fetal development. 
 Several pilot studies suggest that pravastatin may be a good option to prevent and treat 
preeclampsia in women. 
 Rnadomised clinical trial are necessary to confirm the effectiveness of pravastatin to treat 
preeclampsia. 
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SUMMARY 
Pre-eclampsia is a disease of pregnancy affecting 5%–8% of all pregnancies and leading 
cause of maternal and fetal mortality. Despite improvements in the diagnosis, there is no 
effective method of prevention and treatment. While studies in women are of critical 
importance, investigation of pathological mechanisms in pregnant women is necessarily 
limited, and the ability to establish cause and effect relationships, difficult. Mouse models 
have been instrumental in defining pathogenic mechanisms in preeclampsia and in the 
identification of statins as a potential treatment to prevent pregnancy complications 
associated with placental dysfunction. 
Numerous epidemiological studies provided robust evidence demonstrating that pravastatin 
exposure during pregnancy does not affect fetal development. In addition, pravastatin is 
hydrophilic and has a limited passage through the placenta, diminishing any safety concerns. 
Several pilot studies suggest that pravastatin may be a good option to prevent and treat 
preeclampsia in women. While these studies are promising, the effectiveness of pravastatin 
to treat preeclampsia needs to be confirmed by randomized clinical trials. 
 
Key words: pravastatin, preeclampsia, obstetric antiphospholipid syndrome, animal models, 
translational studies 
 
INTRODUCTION 
Preeclampsia (PE) is a pregnancy complication characterized by high blood pressure and 
damage to organ systems such as the liver and kidneys. PE usually begins after 20 weeks of 
pregnancy in women whose blood pressure had been normal. Left untreated, PE can lead to 
serious - even fatal - complications for both mother and fetus. The only available treatment 
for PE is the management of the high blood pressure in the mother with antihypertensive 
medication and lastly, the delivery of the placenta and fetus with the serious risks 
associated with prematurity of the neonate. Identifying a beneficial treatment to improve 
maternal and fetal outcomes in PE remains paramount. In the last 10 years, numerous 
preclinical studies demonstrated that statins might be a beneficial treatment in PE. 
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Emerging data from several pilot experiments validated these results in women.  RCT are 
currently ongoing to confirm these results. 
 
Lessons from the mouse 
While studies in women are of critical importance, investigation of pathological mechanisms 
in pregnant women is necessarily limited, and the ability to establish cause and effect 
relationships, difficult. Mouse models of PE that closely resemble the clinical cases have 
been essential in defining pathogenic mediators in PE and identifying targets for prevention 
and therapy. Several studies in mice identified pravastatin as a potential treatment for 
pregnancy complications associated with placental malperfusion. In this review article we 
will discuss both the preclinical studies and the translational studies that support the use of 
statins to prevent and treat preeclampsia.   
 
 
Pravastatin prevents adverse pregnancy outcomes in a mouse model of antiphospholipid 
syndrome (APS) 
Placental insufficiency is one of the most severe APS-related complications for pregnant 
women. Several in vitro studies demonstrated the binding of antiphospholipid (aPL) 
antibodies to trophoblasts, either cell lines or primary cells from placentas (Di Simone et al 
2015, D’Ippolito et al 2007). However, until recently there was no direct evidence that aPL 
antibodies bind to the placenta in vivo. aPL antibodies, isolated from patients by affinity 
purification were labelled with radioactive indium-111 and single photon emission 
computed tomography (SPECT/CT) was used to visualize the tissue distribution and binding 
of aPL antibodies in a pregnant mouse (Bertolaccini et al 2016). After an intravenous 
injection, radiolabelled antibodies were rapidly cleared from circulation and accumulated in 
the fetal sacs (Bertolaccini et al 2016). Within the fetal sacs, a high count was found in the 
placenta (Bertolaccini et al 2016). Using a non invasive in vivo real time imaging method the 
placenta as a main target organ in APS was demonstrated.  
Given that thrombosis is one of the most common manifestations in APS, pregnancy 
complications in APS have been erroneously attributed to placental thrombosis and infarcts. 
Animal models demonstrated that inflammation, in particular complement activation, 
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rather than thrombosis plays a crucial role in trophoblast injury (Girardi et al 2004). 
Furthermore, histological studies in human placentas also suggest that inflammation 
contributes to placental injury (Viall et al 2015, Stone et al 2006). Regardless of the evidence 
suggesting that APS is a proinflammatory disorder, the primary treatment for pregnant 
women with APS is aimed to preventing thrombosis. Despite drugs such as heparin and low 
dose aspirin, pregnant women with APS are at increase risk for severe preeclampsia and 
intrauterine growth restriction (IUGR) associated with impaired placentation (Laskin et al. 
2009, Branch et al 1992). Animal models of APS allowed the identification of the pathogenic 
mechanisms of aPL and therapeutic approaches to prevent adverse pregnancy outcomes. 
Binding of aPL antibodies to the placenta was associated with complement deposition, 
measured using USPIO-labelled anti C3 antibodies and magnetic resonance imaging (Girardi 
et al, 2015). aPL-induced complement activation in the placenta was associated with signs of 
placental insufficiency characterized by increased neutrophil infiltration, decreased blood 
flow, increased levels of isoprostane STAT-8 –indicative of oxidative stress-  and angiogenic 
imbalance characterized by diminished levels of vascular endothelial growth factor (VEGF) 
(Girardi et al 2015, Redecha et al 2008  Figure 1). A cross talk between coagulation and 
inflammation has been described in the pathogenesis of abnormal pregnancy outcomes in 
APS (Redecha et al 2007, Redecha et al 2008). Tissue factor (TF) was identified as a 
downstream mediator of complement activation (Redecha et al, 2007). TF, the major 
cellular activator of the coagulation cascade, is a key mediator in inflammation and 
trophoblasts injury in the mouse model of obstetric APS (OAPS-mice) (Redecha et al, 2008). 
Using genetically modified mice with selective expression of TF in different tissues, an 
important role of complement-mediated TF expression in maternal neutrophils was 
demonstrated in OAPS-mice (7, Figure 2). aPL-induced TF expression modulates neutrophil 
activity towards a proinflammatory phenotype. In OAPS-mice, TF increases the respiratory 
burst and phagocytosis leading to subsequent trophoblast oxidative injury and adverse 
pregnancy outcomes. TF-mediated proinflammatory phenotype in OAPS involved the 
activation of protease activated receptor 2 (PAR-2). Mice deficient in PAR-2 and treated with 
aPL antibodies exhibited reduced neutrophil activation and normal pregnancies, indicating 
that PAR-2 plays an important role in the pathogenesis of aPL antibody-induced fetal injury 
(Redecha et al, 2008). Statins, simvastatin and pravastatin, downregulate TF and PAR-2 
expression in neutrophils, prevent neutrophil activation, trophoblast injury and fetal death 
 5 
(Redecha et al, 2008). By downregulating TF and PAR-2, statins target the proinflammatory 
phenotype of neutrophils in OAPS leading to normal pregnancies. Pleiotropic effects of 
statins include improvement of endothelial dysfunction, increased nitric oxide 
bioavailability, antioxidant properties, inhibition of inflammatory and prothrombotic 
responses, and proangiogenic responses. All these cholesterol-independent properties 
(Figure 3) may also contribute to the preventive effects of statins in pregnancy 
complications associated with placental insufficiency. In this line, pravastatin prevented 
oxidative stress, placental angiogenic imbalance and neutrophil infiltration in the 15 dpc 
placentas from the surviving fetuses in the OAPS-mouse model (Figure 2) 
 
Pravastatin prevents the onset of preeclampsia in mouse models 
The last decade has seen the emergence of abundant experimental evidence supporting a 
protective role for statins in preventing preeclampsia in mice.  Pravastatin, hydrosoluble 
statin with limited transport across the placenta and thus favorable pharmacokinetic profile 
in pregnancy (Balan et al 2017,   
Nanovskaya et al 2013,  Zarek  et al 2013), prevented the onset of PE in several animal 
models listed below (a-c). The numerous studies in mice paved the way for using pravastatin 
in pregnant women. 
 
a- C1q KO mouse model  
Complement component C1q has an important role in trophoblast migration, spiral arteries 
remodeling, and normal placentation (Agostinis et al 2010, Singh et al  2011). Pregnant C1q-
deficient (C1qKO) mice recapitulate the key features of human PE: hypertension, 
albuminuria, endotheliosis, decreased placental vascular endothelial growth factor (VEGF) 
and elevated levels of soluble VEGF receptor 1 (sVEGFR1 or sFlt-1) that correlate with 
increased fetal death (Singh et al  2011). In addition, decreased blood flow and increased 
oxidative stress are observed in placentas from C1qKO mice. Treatment of C1qKO mice with 
pravastatin restored trophoblast invasiveness, improved placental blood flow, and 
angiogenic balance and, thus, prevented the onset of PE (Singh et al 2011). sVEGFR1 levels 
were reduced and placental VEGF levels were significantly increased in C1qKO mice treated 
with pravastatin compared with untreated C1qKO mice (16). Pravastatin treatment reduced 
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hypertension and albuminuria, signs of preeclampsia associated with adverse pregnancy 
outcomes. Renal damage and endothelial dysfunction were significantly attenuated with 
pravastatin (Singh et al 2011). Studies using the C1qKO mouse model of PE highlighted the 
causative role of impaired trophoblast invasion in the pathogenesis of PE and identified 
pravastatin as a good therapeutic option to prevent PE. 
 
b- CBA/J x DBA/2 mouse model  
While C1qKO pregnant mice exhibit the wide spectrum of clinical features observed in 
human PE, the CBA/J x DBA/2 mouse model of recurrent miscarriage show most of the 
clinical signs except hypertension (Ahmed et al 2010). CBA/J females impregnated by DBA/2 
males develop endothelial dysfunction and angiogenic factors dysregulation leading to 
adverse pregnancy outcomes (Ahmed et al 2010).  Provocatively, as observed in humans 
with PE, the concept of primigravidity - epidemiological landmark of this disease -  is also 
observed in CBA/J x DBA/2 mice, in which only the first pregnancy is affected (Ahmed et al 
2010). CBA/J x DBA/2 mice exhibit albuminuria, endotheliosis, increased sensitivity to 
angiotensin II and increased plasma leptin levels during the first pregnancy that correlates 
with bad pregnancy outcomes. Despite not having hypertension, CBA/J x DBA/2 females 
show severe endothelial dysfunction (Ahmed et al 2010). Antagonism of VEGF signaling by 
sFLT1 seems to be involved in placental and fetal injury in CBA/J x DBA/2 mice. Pravastatin 
restored angiogenic balance, ameliorated glomerular injury, diminished hypersensitivity to 
angiotensin II and prevented intrauterine growth restriction leading to favorable maternal 
and fetal outcomes (Ahmed et al 2010). The CBA/J x DBA/2 model was another helpful tool, 
in the identification of pravastatin as a candidate therapy to prevent preeclampsia and its 
related maternal and fetal complications.  
c- sFLT1-induced preeclampsia mouse models 
The human placenta undergoes high levels of angiogenesis during pregnancy. Failure of 
placental angiogenesis has been linked to the pathogenesis of preeclampsia. It is currently 
believed that soluble factors released by the diseased placenta lead to an antiangiogenic 
state and the onset of preeclampsia. Placenta-derived anti-angiogenic factors, such as sFLT1 
and soluble endoglin (sENG), have been related to the cause and progression of 
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preeclampsia (Maynard et al 2008, Maynard et al 2011). Indeed, systemic administration of 
adenoviral vectors expressing sFLT-1 to mice resulted in PE (Costantine et al 2010). 
Interestingly, pravastatin improved the vascular reactivity in this murine model of PE and 
decreased sFLT-1 levels (Costantine et al 2010). Using this model of PE induced by general 
overexpression of sFLT-1, the authors suggested that pravastatin’s ability to prevent the 
preeclamptic phenotype may be mediated through pleiotropic mechanisms involving a 
prosurvival/ antiapoptotic mitogen-activated protein kinase (MAPK) pathway in the 
trophoblasts (Saad et al, 2016). 
The beneficial effects of statins in PE were also observed in a mouse model of 
preeclampsia that highlights the importance of the placental origin of antiangiogenic factors 
in the pathogenesis of PE. Kumasawa et al developed a model of PE that faithfully reproduces 
many of the human findings of late-onset PE by using a lentiviral vector-mediated placenta-
specific expression system (Kumasawa et al 2011). Transduction of the trophectoderm - that 
provides most of the main and functional components of the future placenta -  of blastocysts-
stage embryos with HIV-I–based self-inactivating lentiviral vectors expressing sFLT-1 resulted 
in the development of PE in mice. In this model, hypertension, proteinuria and intrauterine 
growth restriction were observed (Kumasawa et al 2011). Pravastatin treatment of mice with 
sFLT-1-induced PE, ameliorated symptoms by increasing VEGF-like angiogenic factor placental 
growth factor and diminishing sFLT1 (Kumasawa et al 2011).  
The protective effects of statins in pregnancy were also observed in rats with reduced utero-
placental perfusion pressure (RUPP)-induced hypertension (23). In the rat, pravastatin 
attenuated hypertension, oxidative stress and angiogenic imbalance after placental-
ischaemia was induced by reduction of utero-placental perfusion pressure (RUPP) (Bauer et 
al, 2013).  
 
In vitro studies 
In vitro studies using isolated trophoblasts or endothelial cells have been used to complement 
in vivo studies in the identification of pravastatin mechanism/s. In this line, several studies 
investigating the effects of pravastatin on the release of angiogenic/antiangiogenic factors by 
trophoblasts and endothelial cells were performed. The results obtained from these studies 
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need to be interpreted with caution as concentrations of pravastatin, that do not mimic the 
in vivo plasma concentrations measured in pregnant women, were used in many of these in 
vitro studies. The pharmacokinetic data regarding the use of pravastatin for preventing 
preeclampsia in high-risk pregnant women were reported in a recent study by Costantine and 
colleagues (Costantine et al 2016). This study determined the biodistribution of pravastatin 
in pregnant women for the first time. The maximum (or peak) serum concentration (Cmax) 
that was achieved after an oral dose of 10mg of pravastatin was 14.911.3 ng/mL at 18-24 
weeks and 11.1 6.2 ng/mL  at 30-34 weeks (Costantine et al 2016). The half life of pravastatin 
was 2.10.9 h and 3.0 1.6 h respectively (Costantine et al 2016). In a previous study 
performed in males, the Cmax after oral administration of 20 mg of [14C]-pravastatin was 
27.4  10.7 ng/mL (Singhvi et al 1990). The in vitro studies by Brownfoot and collaborators 
incubated primary placental cells and endothelial cells with  doses  of pravastatin ranging 
from 2 to 2000 M (pravastatin MW: 424,52 g/mol) ( Brownfoot et al 2014, 2015 , 2016). A 
study by Odiari et al, reported that pravastatin augments aPL-induced release of 
inflammatory and antiangiogenic factors and also affects migration in a trophoblast cell line 
(Odiari et al 2012). This study used 500 to 2500 ng/ml of pravastatin, significantly higher than 
the Cmax (  10-15 ng/ml) measured in pregnant women. Thus, these observations might not 
resemble the clinical physiological conditions.   
 
From mice to women – Pilot clinical studies and RCT 
Based on the pathophysiologic similarities between cardiovascular disease and 
preeclampsia and the promising results observed in different animal models in the last 10 
years, treating pregnant women with statins to prevent preeclampsia seems like a good 
therapeutic option. Despite the abundant information provided by animal studies regarding 
the beneficial effects of statins in preventing pregnancy complications and its safety during 
pregnancy in mice and women, translational studies and the organization of RCT was 
significantly delayed. This delay was caused in part because of the misinterpretation and 
misuse of the Food and Drug administration (FDA) categories. Statins were classified as 
category X in 1979 not because they were teratogenic but because there was no indication 
for a woman to take statins while pregnant and no data relating to the effects on a pregnant 
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women and/or the fetus were available at that time (as opposed to the existence of 
evidence of harm) (Manson et al 1996, Girardi 2014). 
The use of drugs in pregnancy for off-label indications such as pravastatin for preeclampsia 
prevention is still challenging (Cleary et al 2014). Importantly, while atorvastatin and 
simvastatin were included in category X, pravastatin was never included in this classification. 
Epidemiological data collected to date demonstrate that statins are not major teratogens 
(Zarek et al 2014, Karalis  et al 2016). Several reports described normal fetal outcomes in 
women that were inadvertently exposed to statins during pregnancy (Bateman et al 2015, 
Lecarpentier et al 2012,  Winterfeld et al 2013). In 2015, based on the fact that the five-
letter system resulted in erroneous assumptions about the actual meaning of the letters, 
the FDA replaced the former pregnancy risk letter categories on prescription drug labelling 
with new and clearer information for both patients and healthcare providers 
(www.drugs.com/pregnancy-categories.html) strong evidence of fetal safety is now 
available. Furthermore, recent studies showing a limited transfer of pravastatin across the 
dually perfused placental supports pravastatin's favourable pharmacokinetic profile in 
pregnancy (Balan et al 2017). That several clinical studies are currently being performed in 
the USA and Europe clearly shows a better understanding of clinicians and patients 
regarding the safe use of statins during pregnancy. 
 
In humans, the first report to suggest the beneficial effects of pravastatin in 
preventing preeclampsia described a patient with antiphospholipid syndrome (APS). The 
APS-patient, with a history of early preeclampsia leading to a still birth at week 26, 
developed preeclampsia in her second pregnancy, despite anticoagulant treatment (Lefkou 
et al 2014). Uterine artery Dopplers showed increased resistance and bilateral notching. To 
prevent intrauterine fetal death as in the previous pregnancy, the patient was 
supplemented with pravastatin.  Addition of pravastatin (20mg/day) to standard of care 
therapy low molecular weight heparin plus low dose aspirin normalised maternal disease, 
blood pressure and proteinuria and reversed abnormal uterine blood flow (Lefkou et al 
2014). A live and healthy baby girl weighing 2830 g was delivered vaginally at 38 weeks with 
no complications. The patient stopped taking pravastatin prior to delivery, in preparation for 
breastfeeding. Interestingly, preeclampsia relapsed shortly after delivery. Pravastatin 
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therapy (20 mg/day) was started again and the preeclamptic features disappeared (Figure 4, 
Lefkou et al 2014). 
A pilot clinical study to examine the effects of pravastatin in women diagnosed with 
PE between 24 and 29 weeks was conducted in Australia (Brownfoot et al 2015). In this 
study, 4 patients –significantly hypertensive (90-105/155-200 mm Hg) and with proteinuria 
ranging from 840 to 2990 mg/24h- were treated with daily pravastatin (40 mg) from the day 
of admission. All women presented growth restricted fetuses. The patients also received 
betamethasone and magnesium sulfate for lung maturation and neuroprotection.  After 
pravastatin treatment symptoms of PE resolved. Pravastatin stabilized blood pressure in 3 of 
the patients and only one patient required antihypertensive medication nifedipine. Delivery 
in these women were triggered by fetal indications rather than worsening of maternal 
disease. Furthermore, serum sFLT-1, sENG and endothelin-1 levels remained stable after 
pravastatin treatment (Brownfoot et al 2015). The authors concluded that pravastatin might 
be a candidate therapeutic strategy for preeclampsia. 
Another study in women with OAPS that did not respond to anticoagulation and 
develop PE was recently published (Lefkou et al 2016). As mentioned before, many women 
with OAPS do not respond to low dose aspirin (LDA) and heparinoids (LMWH) (Laskin et al 
2009) and develop PE. In an attempt to improve obstetrical outcome, the effects of 
pravastatin in this group of women with OAPS was assessed. 21 pregnant women with OAPS 
and an adverse obstetric history - that developed PE and/or severe intrauterine growth 
restriction (IUGR) despite being treated with LDA+LMWH since the beginning of pregnancy - 
participated in this study. A group of 10 women with APS and severe PE and/or IUGR 
received only conventional LDA+LMWH treatment and served as control. Pravastatin 
(20mg/day) was added to conventional treatment in 11 women when signs of preeclampsia 
and or IUGR were observed (Lefkou et al 2016). In the group supplemented with 
pravastatin, placental blood flow increased and hypertension and proteinuria stabilized as 
early as 10 days after treatment (median 14, IQR[10-15]) leading to live birth in all patients 
(Lefkou et al 2016, Table 1).  
In the control group that received only antithrombotic therapy maternal disease did not 
improve and deliveries occurred preterm and only 6 of the 11 neonates survived. Neonates 
spent several months at the neonatology intensive care unit and 3 show abnormal 
development (40, table 1). In the group treated with pravastatin pregnancies were 
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significantly prolonged after diagnosis (13 weeks IQR[8-14]) compared to the group that 
only received LDA+aspirin (4.5 weeks, IQR[2-6] (Lefkou et al 2016, Table 1). Delivery dates in 
the group supplemented with pravastatin were close to term allowing appropriate fetal 
development and preventing admission to the NICU.   No late sequelae were reported for 
the infants in the pravastatin group (Lefkou et al 2016). This study suggests that women 
with refractory OAPS may have improved pregnancy outcomes with pravastatin taken at the 
time of onset of PE or severe IUGR until the end of pregnancy.  
 The studies mentioned above were aimed to ameliorate preeclampsia after the onset of the 
disease. Interestingly, a study by Costantine et al (24) investigated the effectiveness of 
pravastatin in preventing preeclampsia in high risk patients. An initial pilot study in a 
multicenter, double-blind, placebo-controlled, randomized trial (clinicaltrials.gov 
NCT01717586) (Costantine et al 2016), evaluated the utility of pravastatin in preventing 
preeclampsia in women with a history of severe preeclampsia in a prior pregnancy that 
required delivery before 34 weeks. Twenty subjects between 12 and 16 weeks of pregnancy, 
were randomized to pravastatin (10 mg) (n=10) or placebo (n=10). Four women in the 
placebo group developed preeclampsia; three of them showed severe disease compared to 
the pravastatin group, suggesting a beneficial effect of pravastatin in preventing the onset 
of preeclampsia (Costantine et al 2016). In line with the proangiogenic effects of 
pravastatin, a slight but not significant diminution in antiangiogenic factors sFlt-1 and sEng 
and increase in PlGF was observed in the pravastatin group compared to placebo 
(Costantine et al 2016). Birth weight was similar in both groups and no congenital 
abnormalities or developmental abnormalities were observed in the two groups. No 
maternal, fetal or neonatal death was observed (Costantine et al 2016). As previously 
stated, this study provided important information regarding preliminary safety and 
pharmacokinetic data regarding the use of pravastatin in early pregnancy to prevent 
preeclampsia in high risk women. This pilot study was part of a larger RCT that is currently 
taking place at Eunice Kennedy Shriver National Institute of Child Health and Human 
Development Obstetric-Fetal Pharmacology Research Units Network. A proof of principle, 
double-blind, randomised placebo-controlled, multicentre trial of pravastatin to ameliorate 
early onset pre-eclampsia (sTAmP) was recently completed in the United Kingdom 
(https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012968-13/GB). The aim of this 
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trial was to establish whether a significant reduction of angiogenic markers by pravastatin 
will alleviate the severity of early-onset pre-eclampsia in women.  
 
 
CONCLUSION 
The preclinical studies showed promising results on the beneficial effects of pravastatin in 
treating placental insufficiency and laid foundation for the human studies. The mouse 
studies and the pilot human studies emphasize the need of a Randomised Clinical Trials 
(RCT) to confirm these observations. Pravastatin was never included in category X by the 
FDA and due to its hydrophilic characteristics has a minimal transplacental transfer, 
diminishing fetal safety concerns. The new FDA classification that replaced the five-letter 
system together with the abundant evidence demonstrates that pravastatin is safe during 
pregnancy. Other therapeutic strategies to prevent and/or treat preeclampsia have had 
limited success and the only current available therapy is the delivery of the baby, associated 
with high risks due to prematurity. Treatment and prevention of PE with pravastatin is a 
promising option to prevent and treat preeclampsia but RCT should confirm its 
effectiveness. 
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FIGURE AND TABLE LEGENDS 
 
Figure 1. Placental dysfunction in OAPS-mice – protective effects of pravastatin. 
Increased levels of 8- isoprostane (STAT-8), marker of oxidative stress and decreased levels 
of proangiogenic molecule VEGF are observed in 15 dpc placentas from the surviving fetuses 
in aPL-treated mice (OAPS-mice). Increased infiltration of neutrophils is also observed in 
these placentas. Control placentas belong to mice that received normal human IgG (NHIgG). 
Pravastatin prevented all these signs associated with placental dysfunction.  
 
Figure 2. Statins prevent neutrophil activation, trophoblast injury and adverse pregnancy 
outcomes in a mouse model of obstetric APS - proposed mechanism. Maternal aPL 
antibodies bind to the placenta and activate the complement system. Interaction of 
complement split product C5a with its receptor C5aR triggers expression by neutrophils of 
tissue factor (TF), resulting in increased phagocytic capacity and generation of reactive 
oxygen species. Increased neutrophil activity leads to trophoblast injury and ultimately fetal 
death. TF-mediated neutrophil activation proceeds through engagement of protease 
activated receptor 2 (PAR2). Pravastatin prevent C5a-induced upregulation of TF and PAR2 
expression, thereby inhibiting the release of reactive oxygen species and trophoblast 
damage, protecting pregnancies. 
 
Figure 3. Pleiotropic effects of statins. The beneficial effects of pravastatin in preventing 
placental malperfusion/insufficiency might not be entirely due to cholesterol reduction. 
There is now compelling evidence that statins: 1- stimulate trophoblast invasion, 2- increase 
placenta blood flow preventing the release of pathogenic factors. 3- Other beneficial effects 
include: antioxidant properties, release of nitric oxide, protection of the endothelium, anti-
inflammatory and anticoagulant.   
 
Figure 4. Pravastatin improved blood pressure and proteinuria during pregnancy and 
postpartum in a patient with APS refractory to anticoagulation (enoxaparin and aspirin). 
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A- Urinary protein levels (mg/24h) in the patient during pregnancy and postpartum. 
Proteinuria dropped significantly after pravastatin treatment was administered at 
23+1 weeks and at day 5 in the postpartum (Lefkou et al 2014).  
B- Systolic (SBP) and diastolic (DBP) blood pressure variations during pregnancy and 
postpartum. A significant diminution in SBP and DBP was observed after pravastatin 
was added at 23+1weeks and 5 days postpartum. Ninety days after delivery, 
proteinuria and blood pressure remained within normal values (Lefkou et al 2014). 
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Table 1.  Pravastatin improved maternal and fetal outcomes in OAPS refractory to 
antithrombotic therapy. 
Maternal and fetal improvement was observed at 14 days (IQR[10-15])(Lefkou et al, 2016). 
Pregnancy survival improved significantly with pravastatin treatment and deliveries 
occurred close to term diminishing the risks associated with prematurity.  LMWH=low 
molecular weight heparin; LDA=low dose aspirin; PE preeclampsia; IUGR=intrauterine 
growth restriction; PI= pulsatility index, REDV= reverse end diastolic volume (Umbilical 
arteries); BP=blood pressure; Prot=proteinuria; BW=birth weight; NICU=neonatal intensive 
care unit 
 
 
APS PE/IU
GR 
Dopplers 
studies 
LMWH 
+ LDA 
Pravastatin 
time of 
administrati
on 
(weeks) 
(median, 
IQR) 
Threshold 
Achievement 
(BP<130/90 
mmHg; prot 
<300 mg/dl, 
normal 
Dopplers 
(days) 
(median, IQR) 
Pregnancy 
survival 
after 
diagnosis 
(weeks)(me
dian, IQR) 
Time of 
Deliver
y 
(weeks) 
(median
, IQR) 
Neonatal 
outcomes 
YES 
(n=1
0) 
Yes, 
severe 
↑ uterine 
arteries 
PI 
4 
bilateral 
notching 
2REDV 
 
yes NO - 4.5 IQR [2-
6] 
3 stillbirths 
(25-26w) 
 
26.5 
IQR 
[26-32] 
BW:900g 
IQR[580-
1100] 
All admitted at 
NICU 
3 deaths 
3 abnormal 
development 
YES 
(n=1
1) 
Yes, 
severe 
↑ uterine 
arteries 
PI 
3 
bilateral 
notching 
2REDV 
 
yes YES 
24 IQR [23-
26] 
14 IQR [10-
15] 
13 IQR [8-
14] 
36 
IQR[35-
38] 
BW: 2390g 
IQR[2065-
2770] 
2 admitted at 
NICU (twins) 
normal 
development 
in all 
